Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations

BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Marek MRÁZ, Alexandra OLTOVÁ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Václav ŠEDA, Yvona BRYCHTOVÁ, Jiří MAYER, Kamil PARUCH and Martin TRBUŠEK. Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. In 23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere. 2018.

Basic information

• Original name: Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
• Authors: BOUDNÝ, Miroslav (203 Czech Republic, belonging to the institution), Jana ZEMANOVÁ (203 Czech Republic, belonging to the institution), PrashantKumar KHIRSARIYA (356 India, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Jan VERNER (203 Czech Republic, belonging to the institution), Jana ČERNÁ (203 Czech Republic, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), Alexandra OLTOVÁ (203 Czech Republic, belonging to the institution), Zuzana JAŠKOVÁ (703 Slovakia, belonging to the institution), Michaela ŠPUNAROVÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Kamil PARUCH (203 Czech Republic, belonging to the institution) and Martin TRBUŠEK (203 Czech Republic, guarantor, belonging to the institution).
• Edition: 23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere, 2018.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 10606 Microbiology
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/18:00104533
• Organization unit: Faculty of Medicine
• Keywords in English: CHK1; MU380; CLL; TP53

Abstract

Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations, Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations.

Links

• MUNI/A/0968/2017, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V)

Investor: Masaryk University, Category A

• NV15-33999A, research and development project: Name: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality